Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: A multicountry retrospective chart review

Peter Mohr; Felix Kiecker; Virtudes Soriano; Olivier Dereure; Karmele Mujika; Philippe Saiag; Jochen Utikal; Rama Koneru; Caroline Robert; Florencia Cuadros; Matias Chacón; Rodrigo U. Villarroel; Yana G. Najjar; Lisa Kottschade; Eva M. Couselo; Roy Koruth; Annie Guérin; Rebecca Burne; Raluca Ionescu-Ittu; Maurice Perrinjaquet; Jonathan S. Zager

doi:10.2217/mmt-2019-0015

Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: A multicountry retrospective chart review

Peter Mohr, Felix Kiecker, Virtudes Soriano, Olivier Dereure, Karmele Mujika, Philippe Saiag, Jochen Utikal, Rama Koneru, Caroline Robert, Florencia Cuadros, Matias Chacón, Rodrigo U. Villarroel, Yana G. Najjar, Lisa Kottschade, Eva M. Couselo, Roy Koruth, Annie Guérin, Rebecca Burne, Raluca Ionescu-Ittu, Maurice PerrinjaquetJonathan S. Zager

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

8 Citations (Scopus)

Résumé

Aim: To describe treatment patterns among patients with stage III melanoma who underwent surgical excision in years 2011-2016, and assess outcomes among patients who subsequently received systemic adjuvant therapy versus watch-and-wait. Methods: Chart review of 380 patients from 17 melanoma centers in North America, South America and Europe. Results: Of 129 (34%) patients treated with adjuvant therapy, 85% received interferon α-2b and 56% discontinued treatment (mostly due to adverse events). Relapse-free survival was significantly longer for patients treated with adjuvant therapy versus watch-and-wait (hazard ratio = 0.63; p < 0.05). There was considerable heterogeneity in adjuvant treatment schedules and doses. Similar results were found in patients who received interferon-based adjuvant therapy. Conclusion: Adjuvant therapies with better safety/efficacy profiles will improve clinical outcomes in patients with stage III melanoma.

langue originale	Anglais
Numéro d'article	MMT33
journal	Melanoma Management
Volume	6
Numéro de publication	4
Les DOIs	https://doi.org/10.2217/mmt-2019-0015
état	Publié - 1 janv. 2019

Accès au document

10.2217/mmt-2019-0015

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Mohr, P., Kiecker, F., Soriano, V., Dereure, O., Mujika, K., Saiag, P., Utikal, J., Koneru, R., Robert, C., Cuadros, F., Chacón, M., Villarroel, R. U., Najjar, Y. G., Kottschade, L., Couselo, E. M., Koruth, R., Guérin, A., Burne, R., Ionescu-Ittu, R., ... Zager, J. S. (2019). Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: A multicountry retrospective chart review. Melanoma Management, 6(4), Article MMT33. https://doi.org/10.2217/mmt-2019-0015

@article{fe9d1a86d9484c2faf560efaa6024437,

title = "Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: A multicountry retrospective chart review",

abstract = "Aim: To describe treatment patterns among patients with stage III melanoma who underwent surgical excision in years 2011-2016, and assess outcomes among patients who subsequently received systemic adjuvant therapy versus watch-and-wait. Methods: Chart review of 380 patients from 17 melanoma centers in North America, South America and Europe. Results: Of 129 (34%) patients treated with adjuvant therapy, 85% received interferon α-2b and 56% discontinued treatment (mostly due to adverse events). Relapse-free survival was significantly longer for patients treated with adjuvant therapy versus watch-and-wait (hazard ratio = 0.63; p < 0.05). There was considerable heterogeneity in adjuvant treatment schedules and doses. Similar results were found in patients who received interferon-based adjuvant therapy. Conclusion: Adjuvant therapies with better safety/efficacy profiles will improve clinical outcomes in patients with stage III melanoma.",

keywords = "adjuvant therapy, interferon, melanoma, metastatic melanoma, nodal disease, stage III melanoma",

author = "Peter Mohr and Felix Kiecker and Virtudes Soriano and Olivier Dereure and Karmele Mujika and Philippe Saiag and Jochen Utikal and Rama Koneru and Caroline Robert and Florencia Cuadros and Matias Chac{\'o}n and Villarroel, {Rodrigo U.} and Najjar, {Yana G.} and Lisa Kottschade and Couselo, {Eva M.} and Roy Koruth and Annie Gu{\'e}rin and Rebecca Burne and Raluca Ionescu-Ittu and Maurice Perrinjaquet and Zager, {Jonathan S.}",

note = "Publisher Copyright: {\textcopyright} 2019 ",

year = "2019",

month = jan,

day = "1",

doi = "10.2217/mmt-2019-0015",

language = "English",

volume = "6",

journal = "Melanoma Management",

issn = "2045-0885",

number = "4",

}

Mohr, P, Kiecker, F, Soriano, V, Dereure, O, Mujika, K, Saiag, P, Utikal, J, Koneru, R, Robert, C, Cuadros, F, Chacón, M, Villarroel, RU, Najjar, YG, Kottschade, L, Couselo, EM, Koruth, R, Guérin, A, Burne, R, Ionescu-Ittu, R, Perrinjaquet, M & Zager, JS 2019, 'Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: A multicountry retrospective chart review', Melanoma Management, VOL. 6, Numéro 4, MMT33. https://doi.org/10.2217/mmt-2019-0015

TY - JOUR

T1 - Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma

T2 - A multicountry retrospective chart review

AU - Mohr, Peter

AU - Kiecker, Felix

AU - Soriano, Virtudes

AU - Dereure, Olivier

AU - Mujika, Karmele

AU - Saiag, Philippe

AU - Utikal, Jochen

AU - Koneru, Rama

AU - Robert, Caroline

AU - Cuadros, Florencia

AU - Chacón, Matias

AU - Villarroel, Rodrigo U.

AU - Najjar, Yana G.

AU - Kottschade, Lisa

AU - Couselo, Eva M.

AU - Koruth, Roy

AU - Guérin, Annie

AU - Burne, Rebecca

AU - Ionescu-Ittu, Raluca

AU - Perrinjaquet, Maurice

AU - Zager, Jonathan S.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aim: To describe treatment patterns among patients with stage III melanoma who underwent surgical excision in years 2011-2016, and assess outcomes among patients who subsequently received systemic adjuvant therapy versus watch-and-wait. Methods: Chart review of 380 patients from 17 melanoma centers in North America, South America and Europe. Results: Of 129 (34%) patients treated with adjuvant therapy, 85% received interferon α-2b and 56% discontinued treatment (mostly due to adverse events). Relapse-free survival was significantly longer for patients treated with adjuvant therapy versus watch-and-wait (hazard ratio = 0.63; p < 0.05). There was considerable heterogeneity in adjuvant treatment schedules and doses. Similar results were found in patients who received interferon-based adjuvant therapy. Conclusion: Adjuvant therapies with better safety/efficacy profiles will improve clinical outcomes in patients with stage III melanoma.

AB - Aim: To describe treatment patterns among patients with stage III melanoma who underwent surgical excision in years 2011-2016, and assess outcomes among patients who subsequently received systemic adjuvant therapy versus watch-and-wait. Methods: Chart review of 380 patients from 17 melanoma centers in North America, South America and Europe. Results: Of 129 (34%) patients treated with adjuvant therapy, 85% received interferon α-2b and 56% discontinued treatment (mostly due to adverse events). Relapse-free survival was significantly longer for patients treated with adjuvant therapy versus watch-and-wait (hazard ratio = 0.63; p < 0.05). There was considerable heterogeneity in adjuvant treatment schedules and doses. Similar results were found in patients who received interferon-based adjuvant therapy. Conclusion: Adjuvant therapies with better safety/efficacy profiles will improve clinical outcomes in patients with stage III melanoma.

KW - adjuvant therapy

KW - interferon

KW - melanoma

KW - metastatic melanoma

KW - nodal disease

KW - stage III melanoma

UR - http://www.scopus.com/inward/record.url?scp=85100145551&partnerID=8YFLogxK

U2 - 10.2217/mmt-2019-0015

DO - 10.2217/mmt-2019-0015

M3 - Article

AN - SCOPUS:85100145551

SN - 2045-0885

VL - 6

JO - Melanoma Management

JF - Melanoma Management

IS - 4

M1 - MMT33

ER -